Is Zoetis (ZTS) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Zoetis (ZTS), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Zoetis is a member of the Medical sector. This group includes 843 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ZTS is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ZTS's full-year earnings has moved 1.36% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ZTS has returned about 25.21% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.47% on a year-to-date basis. This shows that Zoetis is outperforming its peers so far this year.
Looking more specifically, ZTS belongs to the Medical - Drugs industry, which includes 180 individual stocks and currently sits at #97 in the Zacks Industry Rank. Stocks in this group have lost about 7.88% so far this year, so ZTS is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track ZTS. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zoetis Inc. (ZTS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
